Compare BATRK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BATRK | NUVB |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | BATRK | NUVB |
|---|---|---|
| Price | $38.65 | $8.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $58.00 | $9.63 |
| AVG Volume (30 Days) | 313.9K | ★ 10.2M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,307,000.00 | $26,748,000.00 |
| Revenue This Year | $12.40 | $283.17 |
| Revenue Next Year | $6.78 | $340.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.62 | ★ 1137.19 |
| 52 Week Low | $35.46 | $1.54 |
| 52 Week High | $47.18 | $8.70 |
| Indicator | BATRK | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 76.08 |
| Support Level | $38.00 | $7.46 |
| Resistance Level | $39.98 | $8.24 |
| Average True Range (ATR) | 0.74 | 0.62 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 39.41 | 97.20 |
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.